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Introduction {#sec001}
============

Sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs \[[@pone.0129450.ref001]\]. Despite advances in antibiotic therapy and modern life support, the fatality rate of patients with sepsis has remained as high as 30%-60% worldwide \[[@pone.0129450.ref002]--[@pone.0129450.ref003]\]. Early identification of patients at high risk of dying from sepsis may help initiate rapid and appropriate therapeutic interventions and may have a great impact on sepsis-related morbidity and mortality. However, an accurate assessment of patients at risk for poor clinical outcomes is challenging for clinicians.

Clinical severity scores, such as the Acute Physiology and Chronic Health Evaluation (APACHEII) score and the Sequential Organ Failure Assessment (SOFA) score, have been validated for risk stratification in critical care settings \[[@pone.0129450.ref004]--[@pone.0129450.ref005]\]. However, clinical severity scoring tools tend to be used more in research and are not widely used in clinical decision-making. In recent years, a growing body of clinical research studies has identified blood biomarkers that may confer additional information to estimate disease progression in sepsis \[[@pone.0129450.ref006]--[@pone.0129450.ref008]\].

Procalcitonin (PCT), the prehormone of calcitonin, has been widely investigated in infectious diseases. Apart from its diagnostic value, PCT is also of great value for mirroring the severity of infectious diseases, such as pneumonia. In community-acquired pneumonia (CAP), PCT was shown to be a biomarker of poor outcome \[[@pone.0129450.ref009]--[@pone.0129450.ref010]\]. In patients suffering from ventilator-associated pneumonia (VAP), serum PCT levels could predict death and septic shock \[[@pone.0129450.ref011]\]. More importantly, some studies have demonstrated that PCT may confer prognostic information in sepsis\[[@pone.0129450.ref010]\]. An elevated PCT concentrations were reported to be strongly associated with all-cause mortality in septic patients \[[@pone.0129450.ref012]\]. In addition, patients at high risk of dying may suffered an persistently elevated PCT level. Thus, researches have reported that PCT non-clearance could also predict outcome of sepsis \[[@pone.0129450.ref013]\]. However, those studies had limited patient numbers, and the conclusions were debated. The aim of this meta-analysis was to systematically and quantitatively evaluate all available publications that assessed the prognostic accuracy of a single PCT concentration and PCT non-clearance in adult patients with sepsis and draw conclusions from these studies.

Materials and Methods {#sec002}
=====================

Search strategy and selection criteria {#sec003}
--------------------------------------

We systematically searched studies using PubMed, Embase, Web of Knowledge and the Cochrane Library. The search terms were as follows: (procalcitonin or PCT or \"PCT clearance\" or \"PCT-c\" or \"PCT decrease\" or \"PCT kinetics\") and (sepsis or septicemia or septicemia or septic) and (mortality or prognosis). We include articles written in English and Spanish. No publication date restrictions were applied for searching. We further reviewed the reference list of the selected articles to obtain potentially relevant articles.

Eligible studies had to have a well-defined reference standard for patients involved (sepsis or severe sepsis or septic shock) according to the criteria of the American College of Chest Physicians/Society of Critical Care Medicine \[[@pone.0129450.ref014], [@pone.0129450.ref015]\]. PCT non-clearance was defined as an persistently elevated PCT level. For studies evaluated PCT non-clearance associated with prognosis of sepsis, they should measured ΔPCT/PCT baseline, which means the relative changes in PCT---the difference between the subsequent and baseline measurement- to the baseline PCT. Studies also had to involve the collection of single PCT concentrations or PCT non-clearance data as predictors of all-cause mortality in adult (\>18 years old) septic patients. Further, a 2×2 contingency table should be conducted based on those data. If multiple studies reused the same patient sample, the most recent article or the most informative article was included. For studies that assessed procalcitonin levels associated with different follow-up periods, we chose the most widely used period among the included studies.

Reviews, letters, commentaries, correspondences, case reports, conference abstracts, expert opinions, editorials and animal experiments were excluded. Articles involving pediatric patients were also excluded. Two investigators (Liu D and Su LX) independently executed the search strategy and evaluated the studies. Any disagreement was resolved by a third reviewer (Xie LX). We performed this meta-analysis according to the Preferred Reporting Items for Meta-Analyses (PRISMA) statement checklist (**[S1](#pone.0129450.s001){ref-type="supplementary-material"} & [S2](#pone.0129450.s002){ref-type="supplementary-material"} Files**). To improve our write-up, we have sent our paper to AJE (American Journal Experts) for edited (**[S3 File](#pone.0129450.s003){ref-type="supplementary-material"}**).

Data extraction and quality assessment {#sec004}
--------------------------------------

The following descriptive data were extracted from the original studies: the name of the first author, publication year, the country of origin, study design, clinical setting, assay manufacturer, sample size, endpoints, the prevalence of mortality, the proportion of male patients, mean ages, the definition of PCT non-clearance, sepsis severity, cut-off point, true positives (TP), false positives (FP), false negatives (FN), true negatives (TN), sensitivity (SEN) and specificity (SPE). We contacted the corresponding authors of any study that was missing necessary data or that required clarification. We referred to the original Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist \[[@pone.0129450.ref016]\] for diagnostic studies, and we revised several items to make the criteria more useful for our present meta-analysis. We evaluated the following: (1) information bias (i.e., the representativeness of the study sample and clearly described diagnostic criteria for sepsis); (2) selection bias (i.e., the recruitment of consecutive patients); (3) confusion bias (i.e., the blinding of professionals with influence on patient prognosis to PCT level); and (4) confounding bias (i.e., the exclusion of patients with comorbidities potential linked to PCT levels).

Statistical analysis {#sec005}
--------------------

Statistical analyses were performed using the MIDAS module in STATA version 12.0 (Stata Corporation, College Station, TX) and Meta-Disc 1.4 (XI Cochrane Colloquium, Barcelona, Spain). A *P*-value of less than 0.05 was considered statistically significant. We tabulated TP, FP, FN, and TN rates based on the effect of single PCT levels or PCT non-clearance on all-cause mortality in sepsis patients. Relative risk (RR) was used to assess the predictive value of PCT, which was pooled according to a fixed-effects or random-effects model based on DerSimonian and Lair's method \[[@pone.0129450.ref017]\]. Q-test and *I* ^2^ indexes were calculated to assess inter-study heterogeneity \[[@pone.0129450.ref018]--[@pone.0129450.ref019]\]. Values of 25%, 50% and 75% for the *I* ^2^ test represented low, medium and high heterogeneity, respectively \[[@pone.0129450.ref020]\]. *I* ^2^ values of less than 50% represented acceptable between-study heterogeneity, and the fixed-effects model was selected. Otherwise, the random-effects model was selected. RRs greater than 1 indicated an increased mortality risk from exposure, and RRs less than 1 indicated a beneficial effect.

The presence of a threshold effect on the prognostic accuracy of PCT in sepsis patients was evaluated with the Spearman correlation coefficient between the logits of SEN and SPE. If no threshold effect existed, a bivariate random effects regression model \[[@pone.0129450.ref021]--[@pone.0129450.ref022]\] was used to calculate the pooled SEN, SPE, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), and negative likelihood ratio (NLR). We also constructed a summary receiver operator characteristic (SROC) curve by plotting the individual and summary points of SEN and SPE to assess the overall diagnostic accuracy \[[@pone.0129450.ref023]\].

We performed subgroup analyses to explore the prognostic accuracy of PCT when restricted to different clinical settings (emergency department (ED) and intensive care unit (ICU)), studies using initial PCT levels, and studies involving patients with severe sepsis and septic shock. A univariate meta-regression analysis was performed to explore the sources of potential heterogeneity between studies. The covariates included in the analysis were as follows: the year of publication, the sample size, the prevalence of mortality, the clinical setting, the assay manufacturer, the procalcitonin testing time, the sampling method (i.e., whether studies recruited patients consecutively), and comorbidities (i.e., whether studies excluded patients with comorbidities potentially linked to PCT levels). Publication bias was tested using Deek's funnel plot.

Results {#sec006}
=======

Our database search retrieved 2,098 articles. We eliminated 1,963 articles for various reasons based on the title and abstract, leaving 135 studies to scrutinize with a full text review. In total, 23 studies \[[@pone.0129450.ref024]--[@pone.0129450.ref046]\] fulfilled our eligibility criteria and were finally included (**[Fig 1](#pone.0129450.g001){ref-type="fig"}**). We divided the results of two studies into two parts because investigators reported the diagnostic accuracy separately for two cohorts of patients. Thus, we analyzed 25 datasets. We did not identify any additional relevant articles in the bibliographies of original articles. The characteristics of the included studies are listed in **[Table 1](#pone.0129450.t001){ref-type="table"}** and **[Table 2](#pone.0129450.t002){ref-type="table"}**.

![Flowchart of study selection.](pone.0129450.g001){#pone.0129450.g001}

10.1371/journal.pone.0129450.t001

###### Characteristics of studies associating PCT level with mortality.

![](pone.0129450.t001){#pone.0129450.t001g}

  Author                                   Year   Study design   Clinical setting   Follow-up (days)        PCT assay      Testing time   Sample size (n)   Prevalence of mortality (%)   Severity of sepsis                       Cut off (ng/ml)   SEN (95% CI)   SPE (95% CI)
  ---------------------------------------- ------ -------------- ------------------ ----------------------- -------------- -------------- ----------------- ----------------------------- ---------------------------------------- ----------------- -------------- --------------
  Adamik\[[@pone.0129450.ref024]\]         2000   PR             ICU                ICU mortality           Lumitest PCT   D5             41                61                            Sepsis or severe sepsis                  3                 100            81
  Meng\[[@pone.0129450.ref025]\]           2009   PR+CR          MICU               28-day mortality        PCT-Q          D1             86                37.2                          Severe sepsis                            10                75             66.7
  Yin\[[@pone.0129450.ref026]\]            2013   PR+CR          ED                 30-day mortality        VIDAS          D0             680               33.1                          Sepsis, severe sepsis and septic shock   0.9               61.8           67.3
  Suberviola\[[@pone.0129450.ref027]\]     2013   PR+CR          ICU                In-hospital mortality   KRYPTOR-PCT    D0             137               29.9                          Severe sepsis and septic shock           0.83              95             14.4
  Clec\'h\[[@pone.0129450.ref028]\]        2006   PR+CR          MICU               ICU mortality           KRYPTOR-PCT    D1             36                69.4                          Septic shock                             6                 76             72.7
  Li\[[@pone.0129450.ref029]\]             2014   PR             ICU                28-day mortality        VIDAS          D1             102               41.2                          \-                                       10.65             76.2           81.7
  Masson\[[@pone.0129450.ref030]\]         2014   MRCT           ICU                28-day mortality        Cobas PCT      D1             100               50                            Severe sepsis and septic shock           14.27             56             60
  Yaroustovsky\[[@pone.0129450.ref031]\]   2013   PR             ICU                28-day mortality        VIDAS          D1             81                45.7                          Severe sepsis                            4.76              67             62
  Feng\[[@pone.0129450.ref032]\]           2012   PR             ICU                28-day mortality        VIDAS          D1             102               43                            Sepsis and severe sepsis                 8.5               67.4           73.2
  Jain\[[@pone.0129450.ref033]\]           2014   PR+CR          MICU               28-day mortality        \-             D1             54                50.9                          Sepsis, severe sepsis and septic shock   7                 56.6           70.9
  Dahaba\[[@pone.0129450.ref034]\]         2006   PR             SICU               28-day mortality        Lumitest PCT   D6             69                26.1                          Severe sepsis                            3.2               85             89
  Magrini\[[@pone.0129450.ref035]\]        2013   PR             ED                 In-hospital mortality   VIDAS          D5             96                33.3                          \-                                       \-                87             50
  Savva\[[@pone.0129450.ref036]\]          2011   MPR+CR         ICU                28-day mortality        KRYPTOR-PCT    D1             180               28.3                          Sepsis, severe sepsis and septic shock   0.92              58.8           91.5
  Kenzaka\[[@pone.0129450.ref037]\]        2012   PR             ED                 28-day mortality        PCT-Q          D1             206               9.7                           Sepsis, severe sepsis and septic shock   10                55             61.3
  Giamarellos-Bourboulis\[38a\]            2011   MPR            HW                 Mortality               KRYPTOR-PCT    D1             922               17                            Sepsis, severe sepsis and septic shock   0.12              88.5           27.1
  Giamarellos-Bourboulis\[38b\]            2011   MPR            ICU                Mortality               KRYPTOR-PCT    D1             234               35.5                          Sepsis, severe sepsis and septic shock   0.85              63.9           57.6

PCT = procalcitonin; ICU = intensive care unit; SICU = surgical intensive care unit; MICU = medical intensive care unit; ED = emergency department; HW = hospital ward; PR = prospective recruitment; CR = consecutive recruitment; RR = retrospective recruitment; RCT = random control trial; MPR = multiple-center prospective recruitment; MRCT = multiple-center random control trial; SEN = sensitivity; SPE = specificity; CI = confidence interval.

10.1371/journal.pone.0129450.t002

###### Characteristics of studies associating PCT non-clearance with mortality.

![](pone.0129450.t002){#pone.0129450.t002g}

  Author                                                  Year   Study design   Clinical setting   Follow-up (days)        PCT assay      Definition of procalcitonin non-clearance   Sample size (n)   Mortality (%)   Severity of sepsis                       SEN (95% CI)   SPE (95% CI)
  ------------------------------------------------------- ------ -------------- ------------------ ----------------------- -------------- ------------------------------------------- ----------------- --------------- ---------------------------------------- -------------- --------------
  Tschaikowsky\[[@pone.0129450.ref039]\]                  2011   PR+CR          SICU               28-day mortality        KRYPTOR-PCT    PCT↓ \< 50% within 7d                       51                33.3            Severe sepsis and septic shock           35.3           97.1
  Schuetz\[40a\]                                          2013   RR+CR          ICU                ICU mortality           VIDAS          PCT↓ \< 60% within 72 hr                    154               29.2            Severe sepsis and septic shock           60             67
  Schuetz\[40b\]                                          2013   RR+CR          ICU                ICU mortality           VIDAS          PCT↓ \< 60% within 72 hr                    102               17.6            Severe sepsis and septic shock           78             61
  Mat Nor\[[@pone.0129450.ref041]\]                       2014   PR             ICU                In-hospital mortality   KRYPTOR-PCT    PCT↓ \< 30% within 48 hr                    67                40.3            Severe sepsis                            74.1           55
  Ruiz-Rodriguez\[[@pone.0129450.ref042]\]                2012   PR             ICU                ICU mortality           Lumitest PCT   PCT↓ \< 50% within 48 hr                    27                66.7            Septic shock                             89             72
  Suberviola\[[@pone.0129450.ref043]\]                    2012   PR             ICU                In-hospital mortality   KRYPTOR-PCT    PCT↓ \< 70% within 72 hr                    88                23.9            Septic shock                             52.6           94.2
  Karlsson\[[@pone.0129450.ref044]\]                      2010   PR+CR          ICU                In-hospital mortality   Cobas PCT      PCT↓ \< 50% within 72 hr                    242               24.2            Severe sepsis                            88.7           27.8
  Garcia de Guadiana-Romualdo\[[@pone.0129450.ref045]\]   2014   PR             ICU                In-hospital mortality   Cobas PCT      PCT↓ \< 40% within 48 hr                    100               28              Severe sepsis and septic shock           64.3           62.5
  Guan\[[@pone.0129450.ref046]\]                          2011   PR             ICU                Mortality               Lumitest PCT   PCT↓ \< 25% within 5d                       37                32.4            Sepsis, severe sepsis and septic shock   100            100

PCT = procalcitonin; ICU = intensive care unit; SICU = surgical intensive care unit; ED = emergency department; HW = hospital ward; PR = prospective recruitment; CR = consecutive recruitment; RR = retrospective recruitment; RCT = random control trial; MPR = multiple-center prospective recruitment; MRCT = multiple-center random control trial; SEN = sensitivity; SPE = specificity; CI = confidence interval.

Characteristics of included studies {#sec007}
-----------------------------------

The included studies were published from 2000 to 2014. Thirteen studies \[[@pone.0129450.ref024], [@pone.0129450.ref027], [@pone.0129450.ref028], [@pone.0129450.ref030]--[@pone.0129450.ref031], [@pone.0129450.ref035]--[@pone.0129450.ref036], [@pone.0129450.ref038]--[@pone.0129450.ref039], [@pone.0129450.ref042]--[@pone.0129450.ref045]\] were conducted in Europe, eight \[[@pone.0129450.ref025]--[@pone.0129450.ref026], [@pone.0129450.ref029], [@pone.0129450.ref032]--[@pone.0129450.ref033], [@pone.0129450.ref037], [@pone.0129450.ref041], [@pone.0129450.ref046]\] were conducted in Asia, one \[[@pone.0129450.ref040]\] was conducted in America, and one \[[@pone.0129450.ref034]\] in was conducted in Australia. With one exception \[[@pone.0129450.ref045]\], all studies were published in English. The mean age of patients varied between 45 and 75.8 years, and the proportion of men ranged from 44.8 to 70.4%. Twelve studies \[[@pone.0129450.ref025], [@pone.0129450.ref027], [@pone.0129450.ref030]--[@pone.0129450.ref031], [@pone.0129450.ref034], [@pone.0129450.ref039]--[@pone.0129450.ref045]\] included only patients with severe sepsis or septic shock. The most frequent source of sepsis was pulmonary infection. Three studies \[[@pone.0129450.ref026], [@pone.0129450.ref035], [@pone.0129450.ref037]\] were performed in EDs, one \[38a\] was performed in a hospital ward, and the remaining studies were performed in an ICU. With respect to admission category characteristics, three studies \[[@pone.0129450.ref025], [@pone.0129450.ref028], [@pone.0129450.ref033]\] involved only medical patients, two \[[@pone.0129450.ref034], [@pone.0129450.ref039]\] involved only surgical patients, and the remaining studies involved both medical and surgical patients. Fifteen studies \[[@pone.0129450.ref024]--[@pone.0129450.ref038]\] evaluated the effect of single PCT concentrations on all-cause mortality in sepsis patients. Among these studies, three \[[@pone.0129450.ref024], [@pone.0129450.ref034]--[@pone.0129450.ref035]\] measured PCT level on the fifth or sixth day after admission and twelve collected blood samples within 24 h of sepsis diagnosis. Eight studies \[[@pone.0129450.ref039]--[@pone.0129450.ref046]\] evaluated PCT clearance. Follow-up periods differed across studies, including 28 days \[[@pone.0129450.ref025], [@pone.0129450.ref029]--[@pone.0129450.ref033]\], 30 days \[[@pone.0129450.ref026]\], ICU stays \[[@pone.0129450.ref024], [@pone.0129450.ref028]\] and in-hospital stays \[[@pone.0129450.ref027]\].

Study quality and publication bias {#sec008}
----------------------------------

All studies included a representative sample of patients who underwent PCT testing in practice and clearly described the diagnostic criteria for sepsis. Nine studies \[[@pone.0129450.ref025]--[@pone.0129450.ref028], [@pone.0129450.ref033], [@pone.0129450.ref036], [@pone.0129450.ref039]--[@pone.0129450.ref040], [@pone.0129450.ref044]\] included consecutive patients. Three studies \[[@pone.0129450.ref035], [@pone.0129450.ref042], [@pone.0129450.ref046]\] mentioned the blinding of professionals who influenced patient prognosis to PCT level. Four studies \[[@pone.0129450.ref024], [@pone.0129450.ref029], [@pone.0129450.ref033], [@pone.0129450.ref035]\] excluded patients with comorbidities potentially linked to PCT levels, such as end-organ damage and autoimmune diseases. The Deek's funnel plot of the included studies suggested the presence of publication bias (**[Fig 2A and 2B](#pone.0129450.g002){ref-type="fig"}**).

![Deek's funnel plot asymmetry test for publication bias\
(A. For single procalcitonin concentration; B. For procalcitonin non-clearance). Potential publication bias exists (P\<0.05).](pone.0129450.g002){#pone.0129450.g002}

Data synthesis and meta-analysis {#sec009}
--------------------------------

### Analysis of the association of PCT concentration with mortality {#sec010}

Sixteen studies \[[@pone.0129450.ref024]--[@pone.0129450.ref038]\] with 3126 patients were included in this group. All studies showed that an elevated PCT level was associated with a higher risk of death, with RR ranging from 1.38 to 24.62. Because of the substantial heterogeneity between studies (*I* ^2^ = 63.5%), a random-effects model was used to pool RR estimates. The pooled RR was 2.60 (95% CI, 2.05--3.30) (**[Fig 3](#pone.0129450.g003){ref-type="fig"}**).

![Forest plot of procalcitonin concentration to predict mortality in sepsis.\
The overall pooled RR was 2.60 (95% CI, 2.05--3.30).](pone.0129450.g003){#pone.0129450.g003}

No statistically significant difference was observed when exploring for threshold effect (Spearman correlation coefficient = 0.062; *P* = 0.820). The pooled SEN and SPE were 0.76 (95% CI, 0.67--0.82) and 0.64 (95% CI, 0.52--0.74), respectively (**[S1 Fig](#pone.0129450.s005){ref-type="supplementary-material"}**). The PLR and NLR were 2.1 (95% CI, 1.6--2.8) and 0.38 (95% CI, 0.29--0.51), respectively. The DOR was 6 (95% CI, 3--9). The overall area under the SROC curve was 0.77 (95% CI, 0.73--0.80) (**[Fig 4A](#pone.0129450.g004){ref-type="fig"}**).

![Summary receiver operating characteristic graph of the included studies\
(A. For single procalcitonin concentration; B. For procalcitonin non-clearance).](pone.0129450.g004){#pone.0129450.g004}

A univariate meta-regression analysis was performed to explore the sources of potential heterogeneity between studies. The year of publication, the sample size, the prevalence of mortality, the clinical setting, the assay manufacturer, the PCT testing time, the sampling method (i.e., whether studies recruited patients consecutively), and comorbidities (i.e., whether studies excluded patients with comorbidities potentially linked to PCT levels) were included in the analysis. The results indicated that only PCT testing time was statistically significant for heterogeneity (*P* = 0.020). The initial PCT level was of limited prognostic value in patients with sepsis. Subgroup analyses are shown in **[Table 3](#pone.0129450.t003){ref-type="table"}**.

10.1371/journal.pone.0129450.t003

###### Subgroup analysis.

![](pone.0129450.t003){#pone.0129450.t003g}

  Variables                    No. of studies   No. of patients   SEN (95% CI)       SPE (95% CI)       DOR (95% CI)   PLR (95% CI)    NLR (95% CI)       AUC (95% CI)       Test for heterogeneity (*I*2)   Deek\'s funnel test (*p* value)
  ---------------------------- ---------------- ----------------- ------------------ ------------------ -------------- --------------- ------------------ ------------------ ------------------------------- ---------------------------------
  Overall                      16               3126              0.76(0.67--0.82)   0.64(0.52--0.74)   6(3--9)        2.1(1.6--2.8)   0.38(0.29--0.51)   0.77(0.73--0.80)   63.5                            0.04
  Initial PCT concentration    13               2920              0.72(0.63--0.79)   0.62(0.49--0.73)   4(3--6)        1.9(1.4--2.4)   0.46(0.37--0.56)   0.73(0.69--0.77)   57.5                            0.29
  ICU patients                 12               1222              0.76(0.65--0.84)   0.69(0.55--0.80)   7(4--13)       2.4(1.7--3.6)   0.35(0.24--0.51)   0.79(0.75--0.82)   72.1                            0.12
  Severe sepsis/septic shock   6                509               0.77(0.62--0.87)   0.61(0.38--0.80)   5(2--11)       1.9(1.2--3.2)   0.39(0.25--0.61)   0.76(0.73--0.80)   67.3                            0.17

PCT = procalcitonin; ICU = intensive care unit; ED = emergency department; SEN = sensitivity; SPE = specificity; DOR = diagnostic odds ratio; PLR = positive likelihood ratio; NLR = negative likelihood ratio; AUC = area under the curve; CI = confidence interval.

### Analysis of the effect of PCT non-clearance on mortality {#sec011}

Nine studies \[[@pone.0129450.ref039]--[@pone.0129450.ref046]\] with 868 patients were included in this group. Because the heterogeneity between studies was acceptable (*I* ^2^ = 37.9%), a fixed-effects model was used to pool RR estimates. The pooled RR for mortality was 3.05 (95% CI, 2.35--3.95) (**[Fig 5](#pone.0129450.g005){ref-type="fig"}**).

![Forest plot of procalcitonin non-clearance to predict mortality in sepsis.\
The overall pooled RR was 3.05 (95% CI, 2.35--3.95).](pone.0129450.g005){#pone.0129450.g005}

No statistically significant differences were observed when exploring the threshold effect (Spearman correlation coefficient = 0.133; *P* = 0.732). The pooled SEN and SPE were 0.72 (95% CI, 0.58--0.82) and 0.77 (95% CI, 0.55--0.90), respectively (**[S2 Fig](#pone.0129450.s006){ref-type="supplementary-material"}**). The PLR and NLR were 3.1 (95% CI, 1.5--6.3) and 0.37 (95% CI, 0.25--0.55), respectively. The DOR was 8 (95% CI, 3--22). The overall area under the SROC curve was 0.79 (95% CI, 0.75--0.83) (**[Fig 4B](#pone.0129450.g004){ref-type="fig"}**).

Discussion {#sec012}
==========

In this meta-analysis, we first determined that both single PCT concentrations and PCT non-clearance were strongly associated with all-cause mortality in septic patients. Our evidence may confer additional information for the clinical use of PCT apart from diagnosing infection \[[@pone.0129450.ref047]\] and helping guide therapeutic decision-making \[[@pone.0129450.ref048]\].

We further identified that PCT non-clearance could predict sepsis mortality. The pooled RR for mortality was 3.05 (95% CI, 2.35--3.95). The overall area under the SROC curve was 0.79 (95% CI, 0.75--0.83). We evaluated the prognostic performance of PCT, and the results showed that the diagnostic performance of both a single PCT concentration and PCT clearance is moderate for predicting sepsis mortality.

The implementation of the appropriate therapeutic interventions appeared to be more significant when initiated rapidly at the time of the patient's arrival. Delayed resuscitation has been found to be significantly associated with a risk of death \[[@pone.0129450.ref049]--[@pone.0129450.ref050]\]. The prognostic value of biomarkers have been widely investigated in other meta-analyses \[[@pone.0129450.ref051], [@pone.0129450.ref052]\]. However, those meta-analyses were not immune to unexplained heterogeneity and had a limited number of patients. In our research, PCT non-clearance has emerged as an ideal index to predict prognosis in sepsis. The overall area under the SROC curve was 0.79 (95% CI, 0.75--0.83), which was greater than the results of published meta-analyses of troponins \[[@pone.0129450.ref051]\] and lactate clearance \[[@pone.0129450.ref052]\]. In addition, the heterogeneity between studies was acceptable (*I* ^2^ = 37.9%), which showed our results were reliable. The initial PCT level was of limited prognostic value in patients with sepsis. The pooled SEN and SPE were 0.72 (95% CI, 0.63--0.79) and 0.62 (95% CI, 0.49--0.73), respectively. The overall area under the SROC curve was only 0.73 (95% CI, 0.69--0.77).

Our study has several limitations. First, we failed to assess the diagnostic accuracy of PCT for predicting death in ED patients because of the limited number of available studies. Thus, our results probably cannot be applied to ED patients. Second, also owing to the limited number of available studies, we could not perform subgroup analyses based on different admission categories and sites of infection. Third, we could not determine the optimized cut-off value because we failed to obtain the raw data (the procalcitonin level in each patient) from each original article to map out the ROC curve. We have tried to contact the corresponding authors to obtain the data, but has been difficult to acquire the procalcitonin level of each patients in each trail. And also, we could not conclude the optimal definition of PCT non-clearance required for accurate risk assessment.

Sepsis is a complex pathophysiological process rather than a specific syndrome. Thus far, no ideal biomarker has demonstrated sufficient SEN and SPE to provide clinical utility for predicting sepsis mortality \[[@pone.0129450.ref053]\]. Clinicians need to provide a more comprehensive evaluation of individual patient conditions. Future studies should highlight the combination of procalcitonin with other clinical indexes as part of an overall assessment of sepsis prognosis rather than adopting a biomarker-based approach to the prediction of sepsis mortality. The combination of PCT and other clinical indexes may provide valuable information to assist clinicians in identifying patients at high risk of dying from sepsis. Several studies \[[@pone.0129450.ref008], [@pone.0129450.ref022]\] showed that PCT concentrations were related to APACHEII and SOFA scores. Of the studies included in this meta-analysis, Suberviola \[[@pone.0129450.ref020]\] demonstrated an improved prognostic value when PCT was combined with the APACHEII score. Further studies should be performed to help determine the optimal cut-off point and definition for PCT non-clearance required for accurate risk assessment.

Conclusions {#sec013}
===========

We found that elevated PCT levels and PCT non-clearance were associated with a higher risk of death in patients with sepsis. However, PCT may not be useful as a single index for assessing prognosis because of its moderate diagnostic accuracy, though it may be useful in combination with patients' overall conditions and other clinical indexes. Further studies are needed to define the optimal cut-off point and a definition of PCT non-clearance required for accurate risk assessment.
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